Lincoln National Corp Vertex Pharmaceuticals Inc Transaction History

Lincoln National Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$407.69 - $446.08 $223,414 - $244,451	548 Added 26.6%	2,608 $1.09 Million
Q4 2023 Feb 06, 2024	BUY	$343.0 - $410.68 $244,902 - $293,225	714 Added 53.05%	2,060 $838,000
Q3 2023 Nov 03, 2023	BUY	$338.18 - $362.46 $52,079 - $55,818	154 Added 12.92%	1,346 $468,000
Q2 2023 Aug 04, 2023	SELL	$314.42 - $351.91 $368,500 - $412,438	-1,172 Reduced 49.58%	1,192 $419,000
Q1 2023 May 01, 2023	BUY	$283.23 - $323.1 $9,629 - $10,985	34 Added 1.46%	2,364 $744,000
Q4 2022 Feb 07, 2023	BUY	$285.76 - $321.48 $249,754 - $280,973	874 Added 60.03%	2,330 $672,000
Q3 2022 Nov 03, 2022	BUY	$273.83 - $305.53 $27,656 - $30,858	101 Added 7.45%	1,456 $422,000
Q2 2022 Aug 02, 2022	BUY	$234.96 - $292.55 $3,994 - $4,973	17 Added 1.27%	1,355 $382,000
Q1 2022 May 09, 2022	BUY	$221.42 - $260.97 $15,056 - $17,745	68 Added 5.35%	1,338 $349,000
Q4 2021 Jan 26, 2022	SELL	$177.01 - $223.45 $177 - $223	-1 Reduced 0.08%	1,270 $278,000
Q3 2021 Nov 05, 2021	BUY	$181.39 - $202.99 $44,621 - $49,935	246 Added 24.0%	1,271 $231,000
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $192,177 - $226,627	1,025 New	1,025 $206,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln National Corp with notifications on news.